[Ovarian cancer screening in the general population].
Although the incidence of ovarian cancer is low, mortality from this cancer is high due to discovery at a late stage in the majority of cases. So it seems worthwhile to detect ovarian cancer at an early stage. The clinical presentation is nonspecific, thus screening tools have been evaluated. The most efficient screening technique includes two steps: evaluation of CA-125 and then sonography in case of abnormal results of CA-125. Two main studies have been performed in large populations. The PLCO-study has led to negative results: no reduction in ovarian cancer mortality in the screening group with an important increase in surgical morbidity. The final results of the UKCTOCS-study will be known in two years. Currently these data can't allow the realization of ovarian cancer screening in the general population, mainly due to their natural history.
Département de gynécologie-obstétrique et de génétique, CHUV, 1011 Lausanne. patrice.mathevet@chuv.ch
Patrice
P
Mathevet
Jean-François
JF
Delaloye
D018394:CA-125 Antigen / Q000097:blood; D005260:Female; D006801:Humans; D008403:Mass Screening / Q000379:methods*; D008565:Membrane Proteins / Q000097:blood; D010051:Ovarian Neoplasms / Q000175:diagnosis*
D018394:CA-125 Antigen; C451759:MUC16 protein, human; D008565:Membrane Proteins